Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Oxcarbazepine Tablet Study design [Design Issues]

posted by jag009 – NJ, 2024-07-23 21:50 (705 d 13:09 ago) – Posting: # 24094
Views: 5,076

Hi,

What is your CV for AUC? Like Helmut wrote, Canada requires T/R ratio for Cmax, not 90% CI. Therefore you just need to design and power your study based on CV for AUC.
J

Complete thread:

Oxcarbazepine Tablet Study design AB661 2024-07-13 09:02 [Design Issues]
- ABE or ABEL for Health Canada Helmut 2024-07-14 12:17
- Oxcarbazepine Tablet Study designjag009 2024-07-23 19:50
  - Health Canada ABEL Helmut 2024-07-24 09:06
  - Oxcarbazepine Tablet Study design AB661 2024-08-24 11:00
    - Oxcarbazepine Tablet Study design Helmut 2024-08-24 12:19

Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
234 visitors (0 registered, 234 guests [including 16 identified bots]).
Forum time: 10:59 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas. Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz